Medical News Podcast cover art

All Episodes

Medical News Podcast — 442 episodes

#
Title
1

Beyond Sudden Death: New Risk Markers in Hypertrophic Cardiomyopathy

2

Avoiding Diagnostic Pitfalls in ATTR-CM: Getting the Diagnosis Right the First Time

3

Choosing Among Asthma Biologics

4

With the new school year underway, what health concerns should pediatric clinicians keep on their radar?

5

Could the FDA’s first-in-class RAS inhibitor approval mark a turning point in metastatic pancreatic cancer?

6

Surgical Techniques in Retinal Medicine

7

Safety Signals in Context: Interpreting Long-Term Systemic Therapy Data in Atopic Dermatitis

8

Emerging Data in Stroke Prevention

9

PRIME-PPF: Biomarkers, Imaging, and ILD Treatment

10

Could personalized mRNA therapy be moving closer to clinical practice after positive phase 3 results in melanoma?

11

Bringing It to the Bedside: Humanistic Care and Reproductive Health in Lupus

12

CAR T-Cell Therapy in CLL and Richter’s Transformation: Emerging Evidence and Practical Integration Into Clinical Practice

13

ACC 2026 Highlights: New Frontiers in Myosin Inhibition

14

Safety of Intravitreal Injections

15

As U.S. measles cases reach a 35-year high, the White House is trying to overhaul the childhood vaccine schedule—including plans to split MMR. How are leading medical societies reacting?

16

Personalized Therapy in Atopic Dermatitis

17

Recognizing Type 2–High Asthma in the Clinic

18

As children return to school, could a biologic offer a safer and more practical way to manage multiple food allergies?

19

Systems of Care After Ischemic Stroke and Secondary Stroke Prevention

20

Hypertrophic Cardiomyopathy Obstruction Is Dynamic: How to Avoid Missing Latent LVOTO

21

Are NaV1.8 inhibitors becoming an important new option for acute pain?

22

Reset vs Management: Debate for Treatment-Refractory Lupus Nephritis

23

Beyond the Pain: Migraine, Depression, and Anxiety in Clinical Practice

24

From Early Intervention to Holistic Care: ATTR-CM Updates From ACC 2026

25

PPF Classifications: Where Are We Now?

26

Could Cyclospora explain your patient's persistent summer diarrhea?

27

Systems of Care and Patient Flow for Patients With Retinal Disease

28

Targeting the OX40 Pathway in Atopic Dermatitis: Lessons Learned From Recent Clinical Data

29

Secondary Prevention of Non-Cardioembolic Ischemic Stroke

30

Minimal Residual Disease (MRD) in CLL: Clinical Utility and Practicality

31

Should some patients remain on dual antiplatelet therapy beyond one year after multivessel PCI?

32

How easy is it to get prescription GLP-1s online?

33

Approaches to Pharmacotherapy in ILD, IPF, and PPF

34

Hearing aids help slow brain aging process in adults with mild cognitive impairment

35

Retinal Disease Updates from AAO 2025

36

Could switching direct oral anticoagulants after breakthrough stroke be unnecessary?

37

Are we entering a new frontline era for HER2-positive gastroesophageal cancer?

38

Evolving Strategies in Obstructive Hypertrophic Cardiomyopathy Management

39

Can two common ICU treatments actually do more harm than good?

40

Bispecific Biologics in Atopic Dermatitis: Opportunities, Challenges, and Clinical Implications

41

ATTR-CM in Focus: New Insights on Survival, Arrhythmias, and Phenotype From ACC 2026

42

Personalizing Migraine Care: Integrating Behavioral Therapies and Complementary Medicine

43

Can We Predict Kidney Function Decline in Patients With Lupus Nephritis?

44

Can artificial intelligence prevent a life-threatening hypoglycemic event before it happens?

45

Beyond Asthma and Eczema: Navigating Biologics for Multimorbid Allergic Patients

46

Has the HPV vaccine already eliminated cervical cancer deaths in a generation of young women?

47

Vaccination and Response in Patients With CLL

48

NCCN 2026 Breast Cancer Congress Updates

49

49th Annual Macula Society Meeting: New and Emerging Treatments for Retinal Diseases

50

Can we actually slow the progression of type 1 diabetes after diagnosis?

51

Revisiting Atopic March in the Era of Type 2 Inflammation

52

Can one kidney drug expand treatment to millions more patients?

53

Early Diagnosis: Screening for ATTR-CM in HFpEF and Aortic Stenosis Populations

54

Highlights From ISC 2026: Uncontrolled Hypertension Among Stroke Survivors, PFO Guidelines Updates, and Clinical Trial Participation Benefit

55

Recognizing Cardiovascular Risk in Patients With Lupus Nephritis

56

Could the current Ebola outbreak expose cracks in global public health?

57

AI, Machine Learning, and HRCT in ILD: Challenges and Future Opportunities

58

How Long Is Too Long? Maintenance Therapy for Patients With Lupus Nephritis

59

Facial Pain, Migraine, and the Trigeminal System

60

CLL at ASH 2025: Time Limited Triplet, Timing of Anti-CD20 Therapy, and GAIA/CLL13

61

2026 Macula Society Meeting: New Developments for Retinal Diseases

62

HER2+ Genitourinary Cancers: Targeted Therapy Highlights From ESMO 2025

63

Could a new oral pan-RAS inhibitor finally change the outlook for KRAS-mutated pancreatic cancer?

64

ATTR-CM in 2026: Stabilizers vs Silencers – How Are You Choosing?

65

Highlights From ISC 2026: The CREST-2 Cognitive Substudy and Oral Health and Stroke Risk

66

AI, Machine Learning, and HRCT in ILD: Fibrosis Quantification

67

HER2 in Genitourinary Cancers: Clinical Relevance and Real-World Testing Considerations

68

Could first-line ablation soon replace antiarrhythmic drugs for persistent atrial fibrillation?

69

CLL and ASH 2025: CAR T-cell Therapy and Data on Vaccination and Cancer Screening

70

Could survival in metastatic pancreatic cancer finally be improving?

71

Obstructive Hypertrophic Cardiomyopathy: The Role of Septal Reduction Therapy in the Current Era of Cardiac Myosin Inhibitors

72

Can shingles vaccine drastically cut risk of serious cardiac events?

73

Key Themes From the 49th Annual Macula Society Meeting

74

CGRP and Women’s Health: Migraine Across the Hormonal Lifespan

75

Can stable post-MI patients safely stop beta-blockers after 1 year?

76

AI, Machine Learning, and HRCT in ILD: Standardizing Diagnostics

77

Could giving whole blood in the field improve survival in patients with traumatic hemorrhage?

78

Highlights From ISC 2026: Insights Into Secondary Stroke Prevention From the OCEAN-STROKE Trial

79

CLL at ASH 2025: CLL17

80

Neuromodulation in Migraine Care: Insights From the 2025 IHS Guidelines

81

Diagnosing Obstructive Hypertrophic Cardiomyopathy: Key Considerations for Clinicians

82

ACR 2025: Risk of Proteinuria in Patients With Lupus Nephritis and the Timing of Kidney Biopsy in Patients With SLE

83

Could anticoagulant choice cut bleeding risk in half for patients with acute VTE?

84

2025 San Antonio Breast Cancer Symposium: Evolving First-Line Approaches in Metastatic HER2+ Breast Cancer

85

Could personalized breast screening replace annual mammograms?

86

HER2+ Strategies in GI Cancers: ESMO 2025 Insights

87

Could a new anti-CD20 therapy transform the treatment for systemic lupus?

88

2025 San Antonio Breast Cancer Symposium: Maintenance Therapy Updates in Metastatic HER2+ Breast Cancer

89

ACR 2025: Mortality Risk With Belimumab and GLP-1 Agonists in Lupus and Lupus Nephritis

90

New Data on Risk Factors and Treatment Regimens for Patients With Neovascular AMD and DME

91

Can oral semaglutide reduce heart failure events in patients with heart failure with preserved ejection fraction?

92

2025 San Antonio Breast Cancer Symposium: Key Updates in Early-Stage HER2+ Breast Cancer

93

CLL at ASH 2025: BRUIN Studies and a Triplet for Richter Transformation

94

Could new pulmonary embolism guidelines safely reduce hospitalizations for some patients?

95

Evolving HER2+ Testing and Targeted Therapies in GI Cancers: Latest Insights From ESMO 2025

96

OnabotulinumtoxinA and Migraine: Clinical Insights and Recent Evidence

97

Can achieving prediabetes remission cut CV death and heart failure risk?

98

HER2+ Endometrial and Ovarian Cancers: Targeted Therapy Highlights From ESMO 2025

99

HER2+ Endometrial and Ovarian Cancers

100

Can an oral PCSK9 inhibitor finally close the LDL gap for high-risk patients?

101

Are UTIs being over treated via telehealth—and who actually needs antibiotics?

102

Sequencing Targeted Therapies in the Management of Patients With CLL

103

What does current evidence show about acetaminophen use in pregnancy?

104

Should clinicians routinely ask patients about firearm access?

105

Are missed 2-month vaccines the strongest warning sign for future MMR refusal?

106

Do GLP-1 weight-loss drugs also reduce asthma attacks in teens?

107

What happens to factor Xa reversal strategies now that andexanet is leaving the U.S.?

108

HER2+ Lung Cancer at ESMO 2025

109

HER2+ Lung Cancer Breakthroughs: Sequencing Therapies and Next-Gen Innovations

110

HER2+ Lung Cancer Breakthroughs: New Targeted Therapies Explained

111

Does tirzepatide offer comparable cardiovascular safety to GLP-1 therapy in diabetes?

112

Veterans and Interstitial Lung Disease: Risk Prediction Models and Early Detection

113

Veterans and Interstitial Lung Disease: Providing Specialized Care in Rural and Underserved Areas

114

Highlights From CHEST 2025: Proactive Intervention and Precision Medicine

115

Should remission—not delay—be the new goal for prediabetes?

116

Highlights From CHEST 2025: Earlier Detection and Targeted Interventions

117

Managing CNS Disease in HER2+ Breast Cancer

118

The Changing Landscape of Therapy in HER2-Low and Ultralow Breast Cancer (Part 2)

119

What are the potential health and safety implications for children now that a CDC advisory panel has moved to withdraw the universal birth-dose recommendation for the hepatitis B vaccine in newborns?

120

The Changing Landscape of Therapy in HER2-Low and Ultralow Breast Cancer (Part 1)

121

Updated 2025 Recommendations: Allo-HCT and CAR T-Cell Therapy in CLL (Part 2)

122

Updated 2025 Recommendations: Allo-HCT and CAR T-Cell Therapy in CLL (Part 1)

123

Could a routine antibiotic quietly trigger severe respiratory failure in young patients?

124

Emerging Therapeutics and Biosimilars: Advancing the Future of Osteoporosis Care

125

Sequential Therapy and Switching Strategies in Osteoporosis: Insights for Improved Outcomes

126

How much can staying active in adulthood realy cut dementia risk?

127

Advanced Imaging in Osteoporosis: Integrating Trabecular Bone Score for Enhanced Fracture Risk Assessment

128

How are major medical societies responding to FDA changes to menopause therapy labels?

129

Could over-the-counter painkillers truly outperform opioids after dental surgery?

130

Managing CNS Involvement in HER2+ Lung Cancer

131

Could a chemo-free regimen surpass the standard triplet in HER2+ Breast Cancer?

132

Evolving Second-Line Strategies in HER2+ Lung Cancer

133

First-Line Strategies in HER2+ Lung Cancer

134

Can HER2+ Metastatic Breast Cancer Be Cured?

135

What the PATINA Trial Teaches Us About Treating HER2+ Breast Cancer

136

Could there be a long-awaited breakthrough in first-line therapy for triple-negative breast cancer?

137

Early-Stage HER2+ Breast Cancer

138

Could the choice of diabetes medication change a patient’s cardiovascular risk?

139

Do updated COVID vaccines protect U.S. veterans from severe outcomes?

140

When can stage II–III colon cancer be considered cured after treatment?

141

ICML 2025: Novel Agents in CLL

142

Could SGLT2 inhibitors help lower the risk of sudden cardiac death?

143

ICML 2025: Regimens for Patients With High-Risk CLL

144

ICML 2025: Fixed-Duration and MRD-Guided Regimens in CLL

145

CGRP Migraine Therapies in 2025: Navigating New Safety Warnings for Raynaud’s Phenomenon and Hypertension

146

Should children under 4 still get the MMRV vaccine? The American Academy of Pediatrics says yes

147

Breaking the Migraine Cycle: Understanding Medication Overuse Headache

148

Future Directions in Small Cell Lung Cancer Treatment

149

Small Cell Lung Cancer: Second-line Options Following Maintenance

150

Perspectives on Maintenance Therapy in Small Cell Lung Cancer

151

Should clopidogrel replace aspirin as the standard for CAD prevention?

152

Treat to Target: What it Is and How to Implement

153

Earlier Use of Biologics for Treating Lupus

154

Is FDA-backed elastography poised to replace biopsy as the driver of MASH drug development?

155

2025 Guideline Summary for the Clinical Treatment and Management of Systemic Lupus Erythematosus

156

Emerging Therapies in SLE: Recent Studies and Potential Game-Changing Treatments

157

Non-Invasive Biomarkers in SLE: A Promise of Better Diagnosis, Management, and Personalized Treatment?

158

New Guidelines for the Screening, Treatment, and Management of Lupus Nephritis

159

What does FDA’s approval of generic liraglutide mean for obesity care?

160

How will the first approval for MASH with fibrosis alter treatment pathways?

161

How are telehealth abortion prescriptions reaching ban states?

162

Can a smartphone app reduce suicide attempts after psychiatric hospitalization?

163

Can blood tests reliably guide Alzheimer’s diagnosis in patients with cognitive decline?

164

How do sulfonylureas compare to DPP-4 inhibitors for cardiovascular safety in T2D?

165

Could methotrexate replace prednisone as first-line therapy in lung sarcoidosis?

166

Geographic Atrophy: Where Do We Stand and Where are We Going?

167

Advances in Retinal Therapy: Emerging Strategies for DME and wAMD

168

Richard Ostfeld on Tick-Borne Threats in Changing Ecosystems

169

AI and Telehealth in Diabetic Retinopathy: From Screening to Specialist Care

170

GLP-1s and the Retinal Patient: What Every Eye Care Professional Should Know

171

Floaters: Imaging Tools, Decision-Making, Including Surgery and Patient Counseling

172

Geographic Atrophy: Navigating the Latest Advances in Care

173

“What does full FDA approval of Moderna’s COVID vaccine mean for high-risk kids under 12?”

174

Maintenance Therapy Strategies in Small Cell Lung Cancer

175

ASCO 2025: Emerging Therapies in Small Cell Lung Cancer

176

ASCO 2025: Updates in Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

177

How many avoidable deaths could occur by 2030 if abrupt funding cuts to USAID are not reversed?

178

What’s the latest on the national outbreak of Measles in the US?

179

ASCO 2025 Insights Into HER2+ Breast Cancer: DESTINY-Breast06, SHR-A1811, Rechallenge With T-DXd Post Grade 1 ILD, and More

180

ASCO 2025 Insights Into HER2+ Breast Cancer: DESTINY-Breast09, PATINA, MINI Trial, and More

181

Highlights From ATS 2025: New and Emerging Therapies, Biomarkers, and Imaging for ILDs

182

Highlights From ATS 2025: Approach to the Evaluation and Management of Interstitial Lung Abnormalities—The Official ATS Clinical Statement

183

Could a twice yearly injectable pre-exposure prophylaxis drug help curb the 44-year old HIV epidemic?

184

Emerging and Future Biomarkers for Interstitial Lung Disease

185

Advances and Future Treatment Targets for Interstitial Lung Disease

186

Can an oral diabetes drug reduce hepatic scarring from MASH?

187

The Role of MRD Testing in CLL

188

Toxicity and Treatment Management in CLL

189

CLL Debate: BTKi and BCL2i Combinations in Frontline Treatment of CLL

190

Breaking Barriers in CLL: Immunotherapy with CAR-T and Bispecific Antibodies

191

Can increased physical activity after adjuvant therapy for colon cancer improve disease-free survival?

192

Evolving CLL Therapy: The Power of Doublet and Triplet Regimens

193

Safety of Treatments for HER2-Mutant Lung Cancer

194

Advances in Treating HER2-Mutant Lung Cancer: Efficacy

195

What's fueling the rapid rise of measles in North America despite vaccine availability?

196

Could a new rescue inhaler strategy reduce severe asthma attacks in mild cases?

197

Could ending PEPFAR lead to 1 million new pediatric HIV cases by 2030?

198

Revisiting Anemia Response in Myelofibrosis: Revised International Working Group Criteria

199

Leukemic Transformation in Myelofibrosis: Risks, Realities, and Evolving Strategies

200

Understanding Secondary Myelofibrosis: Diagnosis, Treatment, and Prognosis

201

How much did maternal RSV vaccines and nirsevimab lower infant hospitalizations?

202

Migraine Missteps: Common Diagnostic Pitfalls and How to Avoid Them

203

Game Changer: Are CGRP Inhibitors the New First Line for Migraine Prevention?

204

Could a new HER2-targeted therapy change outcomes in previously treated NSCLC?

205

Lifestyle and Cognitive Health: A discussion with Drs. Elizabeth Kensinger and Andrew Budson

206

Could measles become endemic in the U.S. again within 25 years?

207

What does Mexico’s first fatal H5N1 avian flu case tell us about current risks to humans?

208

Could genetic testing improve prostate cancer screening beyond PSA?

209

Mary Beth Cicero on Reimagining the IUD: A Painless Future for Contraception

210

HER2+ Lung Cancer Treatment: Past, Present, and Future

211

Can statins reduce liver cancer risk in patients with chronic liver disease?

212

HER2 Alterations in Lung Cancer

213

HER2 Biomarker Testing in Lung Cancer

214

Migraine: Updates from the 2024 European Headache Congress

215

Could a new combination improve first-line therapy for myelofibrosis?

216

Migraine Debates: Initial Preventive Therapy and Status Migraine

217

Pharmacological Management of Postpartum Depression: Pros and Cons

218

Barriers to Care Engagement for Postpartum Depression

219

Suicide Risk in Postpartum Depression: Screening and Management

220

Could GLP-1 receptor agonists reduce the risk of blood cancers in type 2 diabetes patients?

221

Can AI reduce false positives and biopsies in breast ultrasound exams?

222

Osteoporosis: Common Questions and Clinical Conundrums

223

Operationalization of a Bisphosphonate “Drug Holiday”

224

Preservation of Perimenopausal Bone Health

225

What are the details around the first measles death in the US in 10 years?

226

Dr. Andrew Budson on consciousness and the role they play on memory

227

How severe is this flu season compared to recent years?

228

Navigating HER2+ Early Breast Cancer: When to Use Neoadjuvant Therapies, Addressing Residual Disease, and Potential Treatment Toxicities

229

Navigating HER2+ Early Breast Cancer: Diagnosis, Treatment Planning, and De-Escalation

230

Why are measles outbreaks surging in Texas and New Mexico?

231

Specialist Spotlight: Parental favoritism and its impact on family dynamics and mental health

232

Specialist Spotlight: Marlie Tondac investigating learning and attention in young children.

233

Can a urine test reduce unnecessary prostate biopsies?

234

Could immunotherapy redefine treatment for Estrogen Receptor positive/HER2 negative breast cancer?

235

Approaching Tough Discussions in ILDs: Lung Transplantation and End-of-Life Issues

236

Insights Into Managing Comorbidities, Discussing Quality of Life, and Benefits of Pulmonary Rehab in Patients With ILDs

237

Could a fully human monoclonal antibody reduce bleeding risk in atrial fibrillation patients?

238

Principles of Selecting Pharmacotherapy for ILDs

239

Diagnosing and Classifying ILDs

240

What is the impact of red meat intake and the risk of dementia and cognitive decline?

241

The Process of Preparing Patients for Food Oral Immunotherapy – International Consensus for Procedural Preparation and Consent: Part 3

242

The Process of Preparing Patients for Food Oral Immunotherapy – International Consensus for Procedural Preparation and Consent: Part 2

243

The Process of Preparing Patients for Food Oral Immunotherapy – International Consensus for Procedural Preparation and Consent: Part 1

244

The Basics of HER2+ in Lung Cancers

245

2024 San Antonio Breast Cancer Symposium Insights on HER2+ Early Breast Cancer: MARGOT Trial, Risk-Reducing Surgeries/Survival, and More

246

What happens to patient care when private equity takes over hospitals?

247

2024 San Antonio Breast Cancer Symposium Insights on HER2+ Early Breast Cancer: TOUCH and DTP Trials and More

248

Clinical Trials in Myelofibrosis: Endpoints

249

Cytopenic Myelofibrosis

250

How many minutes of life does smoking 1 cigarette cost?

251

American Society of Hematology Annual Meeting 2024 – Updates in Myelofibrosis (Part 2)

252

American Society of Hematology Annual Meeting 2024 – Updates in Myelofibrosis (Part 1)

253

American Society of Hematology Annual Meeting 2024 – Updates in CLL (Part 2)

254

American Society of Hematology Annual Meeting 2024 – Updates in CLL (Part 1)

255

What factors are associated with loss to follow-up rates in patients with diabetic retinopathy or diabetic macular edema?

256

Could fewer allergies be linked the gut microbiota of children raised on farms or with pets?

257

Which population is most affected by the rising prevalence of anaphylaxis?

258

Could diet be fueling psoriasis flare-ups?

259

The Impact of Lifestyle and Stress on Memory and Cognition

260

Managing the Signs and Symptoms of Myelofibrosis

261

Clinical Trials in Myelofibrosis: Referral, Recruitment, and Assessment

262

What vaccine preventable disease is surging globally?

263

Postpartum Depression: Importance of Early and Effective Treatment

264

Screening and Diagnosis of Postpartum Depression

265

What is the risk of rhabdomyolysis in patients taking both SGLT2 inhibitors and statins?

266

Postpartum Depression: The Treatment Landscape

267

Shifting the Paradigm: Biologics in the Management of Food Allergy

268

Case-Based Approach to a Patient With Food Allergy

269

A Personalized Approach to Treating Patients With ANCA‑Associated Vasculitis

270

Can starting a medication abortion before confirming an intrauterine pregnancy offer a safe, effective alternative to waiting?

271

Induction Therapy in Patients With ANCA-Associated Vasculitis Part 2: Glucocorticoids and Plasma Exchange

272

Induction Therapy in Patients With ANCA-Associated Vasculitis Part 1: Induction Chemotherapy

273

The Future of Treating HER2+ Lung Cancer (Part 2)

274

Maintenance Therapy in ANCA-Associated Vasculitis

275

Steroid Reduction and Steroid Sparing Approaches to the Management of ANCA-Associated Vasculitis

276

The Future of Treating HER2+ Lung Cancer (Part 1)

277

ANCA-Associated Vasculitis: Renal Manifestations and Guideline Updates

278

Exploring HER2-Low and Ultralow in GI Cancers, Newer Therapies Targeting HER2, and Current Testing Methods

279

Goal-Directed Approach to Long-Term Management of Fracture Risk in Patients With Osteoporosis (Part 2)

280

Goal-Directed Approach to Long-Term Management of Fracture Risk in Patients With Osteoporosis (Part 1)

281

Navigating Toxicities in Gastroesophageal Cancer Treatment and Exploring HER2+ in Biliary Tract Cancers

282

Optimal Use of Denosumab in Patients With Postmenopausal Osteoporosis

283

Using Anabolic Agents in Patients With Postmenopausal Osteoporosis

284

The Role and Function of HER2+ in GI Cancers: Focus on Gastroesophageal and Colorectal Cancers

285

How does poor sleep in midlife impact brain health years later?

286

HER2+ in Gynecologic Cancers (Part 2)

287

HER2+ in Gynecologic Cancers (Part 1)

288

HER2+ Pan-Tumor Basics (Part 2)

289

HER2+ Pan-Tumor Basics (Part 1)

290

Which biologic treatment was the first to receive FDA approval for patients with uncontrolled COPD?

291

Specialist Spotlight: Daniel Daneshvar, MD, PhD on Traumatic Brain Injuries

292

Is hearing loss associated with increased risk of cognitive impairment?

293

What impact does defib pad position have on outcomes for cardiac arrest?

294

Advances in Migraine Treatment (Part 3)

295

Advances in Migraine Treatment (Part 2)

296

Advances in Migraine Treatment (Part 1)

297

Shifting the Focus: Proactive Prevention in Migraine Management

298

What's the first flu vaccine you can take at home?

299

Sinus Headache or Migraine? Unraveling the Truth

300

Treating Through Uncertainty: Selecting Migraine Treatment in Patients Considering Pregnancy

301

Approaches to Migraine Counseling and Treatment in Breastfeeding Patients

302

What is the latest on Cloud-Based AI Endoscopy?

303

What is the latest on the mpox outbreak in Africa and beyond?

304

What is the appropriate duration for beta-blockers after a myocardial infarction?

305

Long COVID affects adolescents differently than younger children

306

Specialist Spotlight: Dr. David Wohl on the current landscape in HIV treatment

307

Brain-computer interface enables man with ALS to speak again

308

Interstitial Lung Abnormalities as a Key Precursor to Interstitial Lung Disease (Part 2)

309

Interstitial Lung Abnormalities as a Key Precursor to Interstitial Lung Disease (Part 1)

310

Specialist Spotlight: Interstitial Lung Diseases for the Non‑Pulmonologist (Part 2)

311

Specialist Spotlight: Interstitial Lung Diseases for the Non‑Pulmonologist (Part 1)

312

FDA approves first nasal spray for treatment of anaphylaxis

313

The Role of Advanced Practice Providers in Diagnosing and Treating Interstitial Lung Diseases (Part 2)

314

The Role of Advanced Practice Providers in Diagnosing and Treating Interstitial Lung Diseases (Part 1)

315

Understanding HER2‑Low Breast Cancer: Challenges of Evolving Definition, Testing Approaches, and Treatment Decision‑Making

316

HER2 Testing in Breast Cancer: Clinical Relevance, Need, Testing Methods, Guidelines, and Interpretation of Results (Part 2)

317

Fourteen modifiable risk factors can help prevent dementia

318

HER2 Testing in Breast Cancer: Clinical Relevance, Need, Testing Methods, Guidelines, and Interpretation of Results (Part 1)

319

Twice-yearly lenacapavir provides 100% protection against HIV

320

Specialist Spotlight: Racial Disparities in Pulmonary Fibrosis (Part 3)

321

Specialist Spotlight: Racial Disparities in Pulmonary Fibrosis (Part 2)

322

Specialist Spotlight: Racial Disparities in Pulmonary Fibrosis (Part 1)

323

Study identifies racial disparities in opioid prescribing

324

Specialist Spotlight:Surgical Care of Patients With Osteoporosis

325

Specialist Spotlight: Perioperative Care of Patients With Osteoporotic Fractures

326

Specialist Spotlight: The Role of Nurse Practitioners and Physician Assistants in the Management of Patients With Postmenopausal Osteoporosis

327

Emerging Potential Treatment Options for Schizophrenia With Negative and Cognitive Symptoms (Part 2)

328

Investigational drug boosts pregnancy rates in women undergoing IVF, ICSI

329

Emerging Potential Treatment Options for Schizophrenia With Negative and Cognitive Symptoms (Part 1)

330

Specialist Spotlight: The Role of Assessment and Screening for Cognitive Impairment in Patients With Schizophrenia (Part 2)

331

Specialist Spotlight: The Role of Assessment and Screening for Cognitive Impairment in Patients With Schizophrenia (Part 1)

332

Specialist Spotlight: Recognizing the Three Symptoms Domains of Schizophrenia in the Outpatient Clinical Practice (Part 2)

333

FDA approves new drug for early Alzheimer's disease

334

Recognizing the Three Symptoms Domains of Schizophrenia in the Outpatient Clinical Practice (Part 1)

335

Islet cell transplantation may help some patients with type 1 diabetes achieve insulin independence

336

2024 ASCO Highlights: Focus on HER2+ Breast Cancer (Part 3)

337

2024 ASCO Highlights: Focus on HER2+ Breast Cancer (Part 2)

338

Weight maintenance possible following semaglutide, liraglutide discontinuation

339

2024 ASCO Highlights: Focus on HER2+ Breast Cancer (Part 1)

340

Lorlatinib shows unprecedented success in advanced NSCLC

341

Tattoo exposure associated with increased risk for malignant lymphoma

342

Novel technique shows promise for significant weight loss

343

Specialist Spotlight: Biosimilars in Retinal Medicine (Part 2)

344

Recovery possible for some patients with TBI removed from life support

345

Specialist Spotlight: Biosimilars in Retinal Medicine (Part 1)

346

Specialist Spotlight: Urothelial Carcinoma Update From the ASCO GU Symposium 2024

347

ASCO Genitourinary Symposium 2024: Late‑Breaking Presentations on EV‑302 and AMBASSADOR

348

Specialist Spotlight: Advanced Urothelial Carcinoma: Considerations in Therapeutic Sequencing

349

Changes in antibody levels predict which children will outgrow peanut allergies

350

Specialist Spotlight: Neoadjuvant Approach to Urothelial Carcinoma: Treatment With Curative Intent

351

Specialist Spotlight: Updates on the Diagnosis of High‑Risk Postmenopausal Osteoporosis (Part 2)

352

Specialist Spotlight: Updates on the Diagnosis of High‑Risk Postmenopausal Osteoporosis (Part 1)

353

USPSTF lowers recommended age for breast cancer screening

354

Secular differences in early life environment affect brain volume, dementia risk

355

Acetaminophen use during pregnancy not associated with neurodevelopmental disorders

356

Physician empathy impacts outcomes in patients with chronic pain

357

Remote monitoring can identify early signs of Alzheimer’s disease

358

More exposure to outdoor light at night linked to higher stroke risk

359

Specialist Spotlight: Alicia Morgans, MD, MPH on the Care of Cancer Survivors

360

No evidence of MRI-detectable brain injury in people with Havana Syndrome

361

Specialist Spotlight: Naushira Pandya, MD, CMD, FACP and Hady Masri, DO on the Unique Risks of the Geriatric Population and RSV: Part 2

362

Psychoactive cannabis use common among high school seniors

363

Specialist Spotlight: Raagini Jawa, MD, MPH, FASAM on Harm Reduction for Individuals with Substance Use Disorders

364

Specialist Spotlight: Jonathan E. Rosenberg, MD and Alicia K. Morgans, MD, MPH on Late‑Breaking Presentations on EV‑302 and AMBASSADOR at ASCO Genitourinary Symposium 2024

365

Specialist Spotlight: Naushira Pandya, MD, CMD, FACP and Hady Masri, DO on the Unique Risks of the Geriatric Population and RSV: Part 1

366

Generics for fingolimod associated with side effects, MS relapse

367

Specialist Spotlight: Alison Buttenheim, PhD on Vaccine Acceptance and Infectious Disease Prevention

368

Previously Untreated Advanced Urothelial Carcinoma: Update From ESMO 2023

369

Study Discussion: Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults

370

Annual breast cancer screening at 40 saves lives

371

Abortion meds can be safely delivered through telemedicine

372

Three Symptom Domains of Schizophrenia: Positive, Negative, and Cognitive Impairment – Part 2

373

Long COVID increases risk for mental health disorders

374

Specialist Spotlight: Sanjai Rao, MD and Dawn Velligan, PhD on Symptom Domains of Schizophrenia in the Outpatient Setting (Part 1)

375

Alzheimer’s disease may be transmissable in rare cases

376

Specialist Spotlight: Raajit K. Rampal, MD, PhD and Ghaith Abu‑Zeinah, MD on Managing Splenomegaly in Myelofibrosis

377

COVID-19 pandemic had a profound impact on diabetes outcomes

378

Specialist Spotlight: Raajit K. Rampal, MD, PhD and Ghaith Abu‑Zeinah, MD on Sequencing JAK inhibitors in Myelofibrosis

379

HPV vaccine highly effective when administered early

380

Oral nirmatrelvir fails to reduce risk of long COVID

381

Modifiable risk factors for young-onset dementia identified

382

Specialist Spotlight: Dr. Krystal Kittle on Aging and Minority Communities

383

Blood test identifies patients at high risk for suicide

384

Specialist Spotlight: Ashton Applewhite on Ageism in Healthcare

385

Specialist Spotlight: Michaela Khan on Running Physiology

386

Specialist Spotlight: Dr. Cara Ocobock on Female Endurance

387

Discontinuation of tirzepatide leads to weight regain

388

Early treatment may induce remission in children born with HIV

389

Brain Care Score predicts dementia, stroke risk

390

Semaglutide reduces cardiovascular event risk in people without diabetes

391

Cat-borne parasite contributes to frailty in older adults

392

Experts create core outcomes set for long COVID

393

American Cancer Society updates lung cancer screening guidelines

394

Adult ADHD associated with increased risk for dementia

395

Long COVID is associated with reduced serotonin levels

396

Specialist Spotlight: Highlights From the 2023 Annual Meeting of American Society of Retina Specialists: Part 2

397

Specialist Spotlight: Highlights From the 2023 Annual Meeting of American Society of Retina Specialists: Part 1

398

Specialist Spotlight: What regimen for retinal disease? Drs. Schneider and Do on the PULSAR study 1-year data

399

Wastewater surveillance provides lead time for pediatric RSV season

400

Specialist Spotlight: How long between injections for retinal disease? Drs. Schneider and Do on the PHOTON study 2-year data

401

Specialist Spotlight: Dr. Tuan Vu on ALS and What's New in Neurology

402

Which therapies have the strongest evidence for smoking cessation?

403

Semaglutide shows promise in obesity-related heart failure

404

Specialist Spotlight: Dr. Chloe Zera Reflects One Year After the End of Roe v. Wade

405

Work stress increases risk for heart disease in men

406

Most older adults not aware of the new RSV vaccine

407

Specialist Spotlight: Does switching cost more? A cost analysis based on DRCR Network Protocol AC when treating patients

408

Specialist Spotlight: What to start DME patient on? A discussion of DRCR Network Protocol AC

409

Pharmacological duodenal exclusion therapy shows promise

410

Specialist Spotlight: Dallas Ducar on Providing Gender-Affirming Care (Part 2)

411

First 10 drugs named for Medicare price negotiations

412

Specialist Spotlight: Dallas Ducar on Providing Gender-Affirming Care (Part 1)

413

RSV in Adults Who Require Hospitalization and Their Management

414

Piroxicam boosts efficacy of emergency contraceptive pill

415

RSV Infections in Immunocompromised Adults

416

Playing football may increase risk of developing Parkinson's disease

417

Myelofibrosis: Updates from EHA 2023

418

Semaglutide reduces cardiovascular risk by 20%

419

Myelofibrosis: Updates from ASCO 2023

420

Topics from the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology (Part 2)

421

Universal flu vaccine elicits strong immune response

422

Topics from the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology (Part 1)

423

Insights from the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology

424

Almost zero risk of HIV transmission with low viral loads

425

Specialist Spotlight on Diversity, Equity, and Inclusion in Retinal Medicine

426

Specialist Spotlight on Myelofibrosis: JAK inhibitor Drug Choice and Dosing Strategy

427

Specialist Spotlight on Myelofibrosis: Approach to Patients With Myelofibrosis and Anemia

428

Antibiotic exposure may affect COVID-19 severity

429

FDA approves first nonprescription oral contraceptive

430

Concomitant meds can hinder antidepressant response

431

Novel obesity drug leads to substantial weight loss

432

USPSTF recommends anxiety screening for all adults aged <65 years

433

Metformin reduces long COVID risk

434

Osimertinib is a game changer in NSCLC

435

Multidrug-resistant keratitis manageable when treated early

436

Oral therapy for sleep apnea could be a game changer

437

Children show good recovery after pediatric inflammatory multisystem syndrome

438

Specialist Spotlight: Clinical psychologist, Dr. Lisa Harris on the psychological impact of eating disorders, obesity, and diet culture

439

Desulfovibrio bacteria associated with Parkinson's disease

440

FDA approves first RSV vaccine for older adults

441

Specialist Spotlight: Dr. Lofton on weight management and the on-label and off-label uses of GLP-1 agonists

442

Brain changes observed in some patients with long COVID